StockData

Cue Biopharma vs Foghorn Therapeutics

CUE and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CUE and FHTX compare

Foghorn Therapeutics is the larger company, worth 5.3 times as much as Cue Biopharma ($109M against $20.6M).

Cue Biopharma grew revenue faster over the last twelve months (354% versus 52.0% for Foghorn Therapeutics).

Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of −176% compared with −436% at Cue Biopharma.

Foghorn Therapeutics scores higher on the StockData Score (9 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCUEFHTX
Size and price
Market cap$20.6M$109M
Share price$2.83$1.83
Change, 1 year−85.0%−61.0%
Change, 5 years−99.3%−86.6%
Beta (5Y)–2.82
Employees29106
StockData Score
Total score89 (better)
Valuation score01 (better)
Growth score22
Performance score11
Health score55
Dividend score00
Valuation
P/S0.5× (better)3.0×
P/B8.9×–
FCF yield−244%−77.6% (better)
Growth
Revenue growth (TTM)354% (better)52.0%
Revenue growth, 5Y average54.2%135% (better)
Profitability
Operating margin−262%−198% (better)
Net margin−436%−176% (better)
FCF margin−133% (better)−229%
Return on equity−1603%–
Financial health
Debt / equity0.00–
Current ratio1.253.36 (better)
Altman Z-score−32.75−4.61 (better)
Piotroski F-score5 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.6%75.6%
Held by insiders17.4%36.3%
Insider net buying, 12 months−$2.3M–
Short interest, % of float14.4%6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.